PD-1 regulates neural damage in oligodendroglia-induced inflammation

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Kroner, Antje ^a   Schwab, Nicholas ^a   Ip, Chi Wang ^a   Leder, Christoph ^a   Nave, Klaus Armin ^b   Mäurer, Mathias ^a,c   Wiendl, Heinz ^a   Martini, Rudolf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c CARITAS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LYMPHOCYTE RECEPTOR; PROTEIN PD 1; PROTEIN PROGRAMMED DEATH 1; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OLIGODENDROPATHY; PHENOTYPE; TRANSGENIC MOUSE;

MUS;

EID: 84887212611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004405     Document Type: Article

References (35)

1. Ip CW, Kroner A, Bendszus M, Leder C, Kobsar I, et al. (2006) Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 26: 8206-8216.
2. Crocker PR (2005) Siglecs in innate immunity. Curr Opin Pharmacol 5: 1-7.
3. Ip CW, Kroner A, Crocker PR, Nave KA, Martini R (2007) Sialoadhesin deficiency ameliorates myelin degeneration and axonopathic changes in the CNS of PLP overexpressing mice. Neurobiol Dis 25: 105-111.
4. Leder C, Schwab N, Ip CW, Kroner A, Nave KA, et al. (2007) Clonal expansions of pathogenic CD8+ effector cells in the CNS of myelin mutant mice. Mol Cell Neurosci 36: 416-424.
5. Lucchinetti C, Bück W, Parisi J, Scheithauer B, Rodriguez M, et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-714.
6. Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458-468.
7. Warshawsky I, Rudick RA, Staugaitis SM, Natowicz MR (2005) Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Ann Neurol 58: 470-473.
8. Gorman MP, Golomb MR, Walsh LE, Hobson GM, Garbern JY, et al. (2007) Steroid-responsive neurologic relapser in a child with a proteolipid protein-1 mutation. Neurology 68: 1305-1307.
9. Hafler DA, De Jager PL (2005) Applying a new generation of genetic maps to understand human inflammatory disease. Nat Rev Immunol 5: 83-91.
10. Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14: 779-782.
11. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813-824.
12. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, et al. (2005) A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 58: 50-57.
13. Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, et al. (2000) Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci 20: 729-735.
14. Kroner A, Schwab N, Ip CW, Sommer C, Wessig C, et al. (2008) The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. Neurobiol Dis in press.
15. Readhead C, Schneider A, Griffiths I, Nave K-A (1994) Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 12: 583-595.
16. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
17. Kobsar I, Berghoff M, Samsam M, Wessig C, Maurer, M, et al. (2003) Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126: 804-813.
18. Mäurer M, Schmid CD, Boots F, Zielasek J, Toyka KV, et al. (2001) Bone marrow transfer from wild type mice reverts the beneficial effect of genetically-mediated immune deficiency in myelin mutants. Mol Cell Neurosci 17: 1094-1101.
19. Mueller M, Wacker K, Ringelstein EB, Hickey WF, Imai Y, et al. (2001) Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol 159: 2187-2197.
20. Magnus T, Schreiner B, Korn T, Jack C, Guo H, et al. (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition implications for immune responses and autoimmunity in the CNS. J Neurosci 25: 2537-2546.
21. Pannetier C, Even J, Kourilsky P (1995) T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 16: 176-181.
22. Ip CW, Kohl B, Kleinschnitz C, Reuss B, Nave KA, et al. (2008) Origin of CD11b+ macrophage-like cells in the CNS of PLP-overexpressing mice: low influx of haematogenous macrophages and unchanged blood-brain-barrier in the optic nerve. Mol Cell Neurosci 38: 489-494.
23. Ip CW, Kroner A, Fischer S, Berghoff M, Kobsar I, et al. (2006) Role of immune cells in animal models for inherited peripheral neuropathies. Neuromol Med 8: 175-189.
24. Kassmann CM, Lappe-Siefke C, Baes M, Brugger B, Mildner A, et al. (2007) Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 39: 969-976.
25. Grundtner R, Dornmair K, Dahm R, Flugel A, Kawakami N, et al. (2007) Transition from enhanced T cell infiltration to inflammation in the myelin-degenerative central nervous system. Neurobiol Dis 28: 261-275.
26. Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27: 195-201.
27. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239-245.
28. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, et al. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32: 666-669.
29. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/ CD3zeta-signalosome and downstream signaling-to PKCtheta. FEBS Lett 574: 37-41.
30. Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, et al. (2007) PD-1/ PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 182: 124-134.
31. Fife BT, Guleria I, Gubbels Bupp M, Eager TN, Tang Q et al. (2006) Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 203: 2737-2747.
32. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, et al. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895.
33. Martin-Orozco N, Dong C (2006) New battlefields for costimulation. J Exp Med 203: 817-820.
34. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 198: 71-78.
35. Ortler S, Leder C, Mittelbronn M, Zozulya AL, Knolle PA, et al. (2008) B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol 38: 1734-1744.